Eight months after Johnson & Johnson committed to a $1.1 billion deal package to partner on Genmab's cancer antibody daratumumab, the FDA has blessed the Phase I/II program with its new "breakthrough" designation.
Antibody technology holds promise for treating a wide array of diseases, and designing new antibodies is a hot area in biotech research right now. One company is developing a new class of antibodies to combat cancer.
he vaccine works by immunizing women in their childbearing years, causing them to pass on protective antibodies to guard infants. Now it's on to a pivotal trial.
Repeat biotech founder Tillman Gerngross has started a new company. Avitide, which Gerngross co-founded with his colleagues at the high-profile startup Adimab, has taken off with an undisclosed amount of Series A financing from the same venture funders that have backed his previous companies.
Researchers have discovered what appears to be an essential growth factor associated with medulloblastoma, the most common malignant brain tumor in children, a finding that could help scientists better target these tumors to provide more effective and less damaging treatments.
Merck Serono and the Feinstein Institute for Medical Research have formed a partnership to develop antibodies to treat systemic lupus erythematosus, an unpredictable disease that has no cure.
Researchers in Texas have come up with a device that's essentially an adaptable diagnostic tool. How so? It can measure 50 different things at once from a single blood drop.
After losing more than 1 million service days during the Iraq and Afghanistan wars to severe diarrhea in troops, the Defense Advanced Research Projects Agency wants to combat the problem by making drugs based on nucleic acids such as DNA rather than the weakened or dead proteins typically used in vaccines.
A virus found in man's best friend may offer a platform for developing a potent human vaccine.
Some 19 months following his abrupt departure from the helm at Novavax, Rahul Singhvi is back with a new start-up with plans to develop a trio of armed-antibody cancer drugs.